OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Part of paid clinical trials in Cities in Alabama, Alabama.
- Sponsor
- AstraZeneca
- Study ID
- NCT00076089
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Roflumilast — DRUG
Study Details
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Key Dates
- Start date
- Dec 31, 2003
- Status verified
- Sep 2016
- Primary completion
- Dec 31, 2005
- Completion
- Dec 31, 2005
Study Design
- Enrollment
- 1,100 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
change in FEV1 from baseline during the treatment period; number of COPD exacerbations.
Locations (35)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| ALTANA Pharma | Cities in Alabama | Alabama | - | - |
| ALTANA Pharma | Cities in Arizona | Arizona | - | - |
| ALTANA Pharma | Cities in Arkansas | Arkansas | - | - |
| ALTANA Pharma | Cities in California | California | - | - |
| ALTANA Pharma | Cities in Colorado | Colorado | - | - |
| ALTANA Pharma | Cities in Connecticut | Connecticut | - | - |
| ALTANA Pharma | Cities in Florida | Florida | - | - |
| ALTANA Pharma | Cities in Georgia | Georgia | - | - |
| ALTANA Pharma | Cities in Illionois | Illinois | - | - |
| ALTANA Pharma | Cities in Iowa | Iowa | - | - |
| ALTANA Pharma | Cities in Kentucky | Kentucky | - | - |
| ALTANA Pharma | Cities in Louisiana | Louisiana | - | - |
| ALTANA Pharma | Cities in Massachusetts | Massachusetts | - | - |
| ALTANA Pharma | Cities in Minnesota | Minnesota | - | - |
| ALTANA Pharma | Cities in Missouri | Missouri | - | - |
| ALTANA Pharma | Cities in Montana | Montana | - | - |
| ALTANA Pharma | Cities in Nebraska | Nebraska | - | - |
| ALTANA Pharma | Cities in Nevada | Nevada | - | - |
| ALTANA Pharma | Cities in New Hampshire | New Hampshire | - | - |
| ALTANA Pharma | Cities in New Jersey | New Jersey | - | - |
| ALTANA Pharma | Cities in New York | New York | - | - |
| ALTANA Pharma | Cities in North Carolina | North Carolina | - | - |
| ALTANA Pharma | Cities in Ohio | Ohio | - | - |
| ALTANA Pharma | Cities in Oklahoma | Oklahoma | - | - |
| ALTANA Pharma | Cities in Oregon | Oregon | - | - |
| ALTANA Pharma | Cities in Pennsylvania | Pennsylvania | - | - |
| ALTANA Pharma | Cities in Rhode Island | Rhode Island | - | - |
| ALTANA Pharma | Cities in South Carolina | South Carolina | - | - |
| ALTANA Pharma | Cities in Tennessee | Tennessee | - | - |
| ALTANA Pharma | Cities in Texas | Texas | - | - |
| ALTANA Pharma | Cities in Utah | Utah | - | - |
| ALTANA Pharma | Cities in Vermont | Vermont | - | - |
| ALTANA Pharma | Cities in Virginia | Virginia | - | - |
| ALTANA Pharma | Cities in West Virginia | West Virginia | - | - |
| ALTANA Pharma | Cities in Wisconsin | Wisconsin | - | - |
Find similar trials in Cities in Alabama, AL
By condition
By specialty
Related Studies
- Emphysema Research Registry and Biosample RepositoryRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) StudyRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- : Vascular Function in Health and DiseasePHASE1 · Recruiting · Russell Richardson · Salt Lake City, Utah
- Hyper Polarized Xenon-129 MRI vs Xenon-133 ScintigraphyPHASE1/PHASE2 · Recruiting · University of Virginia · Charlottesville, Virginia